Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Akelius redeems all preference shares

The Board of Directors of Akelius Residential Property AB (publ) has decided on a mandatory redemption of all 18,835,606 preference shares at SEK 347.5 per preference share,of which SEK 2.5 per preference share is accrued dividend.In total, the redemption amount is SEK 6,545 million. The redemption of the preference shares is carried out in accordance with the redemption provision in § 5 paragraph 7 in the articles of association.The company’s share capital will, through the redemption, be reduced by EUR 1,099,643.25.An amount corresponding to the reduction of the share capital

Sedana Medical adjusts and clarifies its long-term financial targets

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company will no longer communicate a profit target for the period until registration of IsoConDa in Europe. It also clarifies the sales target of SEK 500 million three years after European registration only applies to sales in Europe.In addition to Sedana Medical’s ambition to grow 20 percent a year before the registration of IsoConDa in Europe, the company has also previously stated that the EBITDA should not be significantly negative. As the European registration is getting closer, and registration work for

Flex LNG – Invitation to Q3 2019 presentation and webcast

Hamilton, Bermuda, November 8, 2019 Flex LNG Limited (“Flex LNG” or the “Company”) will release its financial results for the quarter and the nine months ended 30 September 2019 on Wednesday 20 November 2019 on or about 07:00 am CET. In connection with the earnings release, a webcast and conference call will be held at 15:00. CET. In order to attend the webcast and/or conference call you may do one of the following: Attend by Webcast: Use to the follow link prior to the webcast: https://edge.media-server.com/mmc/p/hhpedipx       Attend by Conference Call: Applicable

I.A. Hedin Bil AB interim report Q3 2019

New car sales saw an overall positive development during the third quarter after a slow down during spring. Profit margins from sales of used cars continued to improve and aftermarket services improved during the third quarter.Gothenburg, 11th of November 2019   The market for new car registrations in Sweden recovered substantially in the third quarter compared to last year. Quarterly comparisons are made difficult because of changes in the regulatory landscape, especially with the introduction of Bonus Malus in the Swedish market. Up until and including the third quarter this year, the

The following people have been appointed as members of SciBase Holding’s nominating committee for the Annual General Meeting in 2020:

Frederick Johansson (representing SEB Venture Capital, Filip Petersson (SEB pensionsstiftelse), Christer Jönsson (Fouriertransform), Tord Lendau (Chairman of the Board). The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on May 16, 2019.The Annual General Meeting of SciBase Holding AB (publ) will be held on May 14, 2020 in Stockholm.Shareholders who wish to have an item considered at the Annual General Meeting

Flowscape wins prestige customer in Finland

Flowscape has received an order, on our world-leading room booking solution, for one of Finland's largest companies. The first order is for phase one and comprises one floor in the customer's Helsinki head office. The customer's plan is to install on the remaining 6 floors shortly after New Year. The order value for the first floor is 300,000 SEK over three years.“We are very pleased that a large company in Finland has chosen Flowscape as supplier to their head office. This strengthens our position in the Finnish market and once again shows that Flowscape has one of the world's strongest

Tim Hortons[®] announce opening date for new Drive Thru Restaurant in Glengormley

Tim Hortons ®, the iconic Canadian coffee chain, will open the new drive thru restaurant at 261-263 Antrim Road, Glengormley, on Tuesday 19 November at 12pm. The first 100 customers at the new restaurant will be given a free lunch combo meal to celebrate the opening. The lucky, early-bird customers can treat themselves to a Tims ® Crispy Chicken Sandwich, or any Grilled Wrap, with a portion of potato wedges and a small drink all free of charge. Meanwhile the very first person in the queue for both the drive-thru, and the restaurant, will receive

Oboya signs strategic framework agreement in China

Oboya Horticulture Industries AB ("Oboya" or "The Company") has, through its wholly-owned subsidiary in China, signed an unconditional framework agreement with a leading cultivation company in industrial cannabis during the ongoing China International Import Expo trade fair. Oboya has signed an unconditional framework agreement with a leading industrial cannabis cultivation company in China. The agreement does not impose any obligation to order. As a first step in the collaboration, a study will be conducted where the customer's needs are to be analyzed. The total order value for

Bravida Norway strengthens operations in Trøndelag – acquires additional electricity company in Orkdal

Bravida takes over operations in Orkdal Installasjon AS, thus strengthening its operations in electrical installations in Orkdal. The company has an annual turnover of around NOK 17 million and 14 employees.Orkdal Installation AS was established in 1991 in Orkdal municipality, near Trondheim in central Norway. The company offers installations and services in electricity and security, to both companies and individuals. In 2018, Bravida acquired another electricity company in the area, Orkla Elektriker AS. With the new acquisition, Bravida further strengthens the local position. Petter

Offer document regarding Vonovia’s mandatory cash offer to the shareholders of Hembla has been made public

THE OFFER REFERRED TO IN THIS PRESS RELEASE IS NOT BEING MADE, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG OR JAPAN OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER, ACCORDING TO LEGISLATION AND REGULATIONS IN SUCH JURISDICTION, WOULD BE PROHIBITED BY APPLICABLE LAW. THE OFFER IS NOT BEING MADE TO (NOR WILL TENDER OF SHARES BE ACCEPTED FROM) PERSONS IN THESE COUNTRIES OR PERSONS IN ANY OTHER JURISDICTIONS WHERE TENDER OF SHARES WOULD DEMAND FURTHER DOCUMENTATION, FILINGS OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED PURSUANT TO SWEDISH LAW. SHAREHOLDERS IN THE UNITED

Nomination Committee appointed for LeoVegas ahead of 2020 Annual General Meeting

In accordance with the principles for appointment of the Nomination Committee of LeoVegas AB (publ) (“the Company” or “LeoVegas”) adopted by the Annual General Meeting on 29 May 2019, the Nomination Committee shall consist of five members appointed by the four largest shareholders. The fifth member shall be the Chairman of the Board.Based on the above, the Nomination Committee ahead of the 2020 Annual General Meeting has been determined to consist of the following persons, who together represent approximately 22% of the number of shares and votes in the Company as per 30 September 2019:

Aptevo Therapeutics and Alligator Bioscience present new preclinical data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting

Preclinical Data Show that ALG.APV-527 is Well Tolerated with Repeated Dosing Preliminary in vivo Data Show that ALG.APV-527 has Potent Anti-tumor Activity and Induces an Immunological Memory ResponseSeattle, WA and Lund, Sweden – November 8, 2019 – Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics and Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy today announced that new preclinical data for ALG.APV-

Geneva Goes Green - Driving bans: Geneva sets an example in the fight against air pollution

Berlin, 08.11.2019. The canton of Switzerland's second largest city with 200,000 inhabitants has decided to introduce an environmental zone for Geneva and the surrounding area  from 15 January 2020. This is a temporary zone that is activated during an air pollution peak with a few hours' advance and then applies between 6:00 and 22:00. One of the reasons for this measure is the high number of deaths caused by air pollution. In 2018, there were around 3,000 deaths throughout Switzerland. Depending on the emission

Delisting of Nordea Smart Beta Eurozone Equity UCITS ETF

The Board of Directors of Nordea Markets ETF has decided to remove the share classes of the Sub-Fund, Nordea Smart Beta Eurozone Equity UCITS ETF from Nasdaq Stockholm. The decision is based, and in accordance with the Prospectus dated October 2019, on the fact that the NAV of the Sub-Fund has been less than EUR20 million for a significant period. Therefore, Nordea Markets ETF will apply for delisting from Nasdaq Stockholm of: Share class name ISINNordea Markets ETF - Nordea Smart Beta LU1820829452Eurozone Equity UCITS ETF – Class I (EUR)ACC

Immunovia Interim Report, January-September 2019

“The Commercial Test Model” study is going to deliver results according to plan at year-end 2019, and IMMray™ PanCan-d is thus on track for sales start in Q3 2020. The Key Opinion Leader networks continue to grow and provide the company with world-leading expertise, both in the main focus area of pancreatic cancer, with a total estimated market of USD 4.4 billion, as well as in the discovery projects for lung cancer and autoimmunity, with multiple larger total markets. “The third quarter was an exciting and eventful time for us at Immunovia following the groundbrea-king results of the

AcuCort gives an update on the continued work concerning the bioequivalence study for US registration

AcuCort AB (Spotlight Stock Market: ACUC) gives further information on the results from the second bioequivalence study for a US registration, and reports on the efforts to establish the causes of non-achieved bioequivalence and to develop options for the continued work with registration and commercialization of the company’s drug candidate ISICORT®.AcuCort has previously reported positive results from the first of the two studies for registration in the US, and from the bioequivalence study on which the company’s submitted application for marketing authorization in Sweden is based. The

Ortoma initiates expansion with module for spine surgery

Safer and more accurate surgical outcome of spine surgery with Ortoma’s surgical system After a period of assessment of Ortoma’s surgical system for hip surgery, the company is now taking the step next step and initiates expansion of Ortoma Treatment Solution (OTS) with a module also for spine surgery.– The conclusion after a number of performed surgeries is that our surgical system provides distinct advantages including very high accuracy and safety, which is decisive for the surgical outcome also for spine surgery. Therefore, the board of directors has taken the decision to expand the

Swedbank congratulates Anna Breman

The General Council of the Swedish Riksbank has today appointed Swedbank's Chief Economist Anna Breman as Deputy Governor. She most recently comes from the role of Chief Economist and Head of Macro analysis at Swedbank, where she has contributed greatly with her broad and deep knowledge of the financial market from both a national and a global perspective.Anna Breman has successfully led Swedbank's Global Macro Research Team, which is responsible for all global, regional and national macro analysis at Swedbank. Anna has also helped build Swedbank's team of senior and knowledgeable experts

Orexo to Present at Jefferies 2019 Healthcare Conference

Uppsala, Sweden – November 8, 2019 - Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the company will present at the Jefferies Healthcare Conference on Wednesday, November 20, 2019, at 10.40 am GMT at the Waldorf Hilton Hotel in London, UK. President and CEO, Nikolaj Sørensen, will provide an update on Orexo’s market, sales development, pipeline progression and the growth strategy, focusing on broadening the product portfolio and building a presence in the increasingly important and complementary digital

BerGenBio presents updated phase 2 NSCLC clinical and translational data for bemcentinib in combination with KEYTRUDA®

· BerGenBio’s proprietary Composite AXL Tumor-Immune Score predicts patients that have significantly prolonged clinical benefit · Primary endpoint of ORR in cohort A met, in predominantly PD-L1 low/negative patients · Combination is 5-fold more active in composite AXL positive patients (33% ORR) vs AXL negative patients (7% ORR) · Secondary endpoint, median Progression Free Survival of 8.4 months in composite AXL score positive patients, exceeds expectations, 3-fold longer than for composite AXL negative patients. Bergen, Norway, 8 November 2019 – BerGenBio ASA (OSE:BGBIO), a

EAB Group Plc: Schedule for financial reporting in 2020

EAB Group Plc, Stock Exchange Release, 8 November 2019, 1.45 p.m. (EET) EAB Group Plc: Schedule for financial reporting in 2020 In 2020 EAB Group Plc (Company) will publish the following financial releases: · Financial statements bulletin 2019 will be published on Friday 14 February 2020. · Annual Report 2019 will be published on Friday 13 March 2020.  · Half-year financial report January–June 2020 will be published on Friday 28 August 2020. The financial bulletins will be published in Finnish and English. The bulletins and the financial reports can also be read in

EIB lends EUR 40 m to Fazer Group for research and development

European Investment Bank (EIB) finances Fazer’s research and development activities, including the construction of an innovative xylitol manufacturing facility. A EUR 40m EIB loan has been granted for activities to be rolled out at Fazer in Vantaa, Lahti and partially also in Lidköping.The EIB and Fazer have signed a EUR 40 million loan agreement to finance Fazer’s research, development and innovation (RDI) activities in the coming years. Specifically, Fazer will fund the construction of a new plant, where the sweetener xylitol will be extracted from discarded oat hulls. This will be built

Catena Media Nomination Committee 2020 AGM appointed

Catena Media plc´s (CTM) Annual General Meeting will be held in Malta on Friday 15thof  May 2020. In accordance with the resolution at Catena Media´s AGM held on 2ndof May 2019, it is hereby announced that the company´s major owners have appointed a Nomination Committee.In accordance with the decision by the Annual General Meeting 2019, the Nomination Committee of Catena Media Plc. shall consist of four members. The three largest share-holders who wish to participate in the committee are entitled to appoint one member each. In addition, the Chairwoman of the Board of Directors of Catena

QuickCool AB (publ): European High Growth Opportunities Securitization Fund requests conversion of convertible bonds

European High Growth Opportunities Securitization Fund has by notice to the board of directors of QuickCool AB (Publ) ("QuickCool") called upon its right to conversion of convertible bonds previously issued in accordance with the financing solution announced by QuickCool through a press release on 21 June 2018.QuickCool has received notification from European High Growth Opportunities Securitization Fund regarding conversion of convertible bonds into 999 999 shares in QuickCool, corresponding toSEK 1 100 000 of the convertible loan. The conversion price per share is SEK 1,10. Upon

There are no items matching the current filter
There are no more items matching the current filter
Back to top